Wednesday, October 14, 2026

USD/EUR Bullish Momentum: 0.93% Up In The Last 10 Sessions

USD/EUR Bullish Momentum: 0.93% Up In The Last 10 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 0.93% for the last 10 sessions. At 04:07 EST on Friday, 21 June, USD/EUR (USDEUR) is $0.94.

USD/EUR's yearly highs and lows, it's 5.536% up from its 52-week low and 2.194% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was 0.06%, 0.06%, and 0.27%, respectively.

USD/EUR's highest amplitude of average volatility was 0.23% (last week), 0.29% (last month), and 0.27% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be oversold (<=20).

News about

  • Usd/jpy flat lines below 158.00, bulls turn cautious amid subdued USD price action. According to FXStreet on Wednesday, 19 June, "Apart from this, speculations that Japanese authorities might intervene to prop up the domestic currency further contribute to capping the USD/JPY pair. ", "This, however, does little to impress the JPY bulls or provide any meaningful impetus to the USD/JPY pair, though subdued US Dollar (USD) price action continues to act as a headwind for spot prices."
  • Usd/jpy price analysis: steadies as asian session begins, above 158.00. According to FXStreet on Wednesday, 19 June, "The USD/JPY remains flat as Thursday's Asian session begins, yet it printed minuscule gains of 0.15% on Wednesday. ", "Conversely, sellers can challenge key support levels if USD/JPY drops below 157.00. "
  • Usd/jpy holds steady near 158.00 mark, just below its highest level since late April. According to FXStreet on Thursday, 20 June, "Apart from this, the underlying bullish tone across the global equity markets is seen denting demand for the safe-haven JPY and lending support to the USD/JPY pair. ", "This, along with the US bond yields and Fedspeak, will influence the USD price dynamics and provide some impetus to the USD/JPY pair. "
  • Usd/jpy bulls turn cautious near 159.00, highest since April amid intervention fears. According to FXStreet on Friday, 21 June, "Nevertheless, the USD/JPY pair remains on track to end in positive territory for the second straight week as investors now look forward to the release of the global flash PMI prints for some meaningful impetus. ", "This adds to uncertainty if the BoJ will hike interest rates in July or later in the year, which, along with the underlying bullish sentiment across the global equity markets, dents demand for the safe-haven JPY and acts as a tailwind for the USD/JPY pair."

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com